Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Lee Seung-heon Signals Caution on Rate Hikes, Supports Higher Property Taxes to Cool Korea’s Housing Market 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Nikkei 225 Hits Record High Above 56,000 After Japan Election Boosts Market Confidence 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
Asian Currencies Stay Rangebound as Yen Firms on Intervention Talk 
Sanofi, a pharmaceutical company headquartered in Paris, France, announced its acquisition of the American biopharmaceutical firm, Kadmon. It was revealed that the deal is worth $1.9 billion and the French drugmaker made the purchase to further strengthen the growth of its transplant business line.
Sanofi shared the news about its latest acquisition on Wednesday, Sept. 8. The firm confirmed its purchase of Kadmon Holdings just a month after buying Translate BIO, another US-based biotech company for $3.2 billion.
According to Reuters, Sanofi offered to buy Kadmon in cash at $9.50 per share which is equivalent to more or less $1.9 billion. It was mentioned that both of the firms’ boards did not oppose the deal and granted approval for the deal to proceed.
“We are transforming and simplifying our General Medicines business and have shifted our focus on differentiated core assets in key markets,” Sanofi’s executive vice president of general medicines, Olivier Charmeil, said in a press release. “We are thrilled to add Kadmon's Rezurock to our well-established transplant portfolio. Our existing scale, expertise, and relationships in transplant create an ideal platform to achieve the full potential of Rezurock, which will address the significant unmet medical needs of patients with chronic graft-versus-host disease around the world.”
On the other hand, Kadmon’s president and chief executive officer, Harlan Waksal, M.D., said that they were thrilled as Sanofi acknowledged the value of its Rezurock oral medicine for GVHD or chronic graft versus host disease, a crippling immune-mediated condition that affects many blood cancer patients who underwent bone marrow transplants.
He added that by making use of the pharmaceutical company’s global resources and well-known expertise in developing and selling new medicines, Rezurock is now in a better position for international accessibility. Kadmon’s Rezurock is a drug for the treatment of both adults and patients who are 12 years and older. It was approved by the U.S. Federal Drug Administration (FDA) in July.
Finally, with Sanofi’s acquisition of Kadmon, the said medicine will now become the French pharma company’s third drug under its transplant medicine business. This is also its third major purchase in this year alone.
